Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 163Radiosurgery 129Radiotherapy 107Bevacizumab 98Magnetic Resonance Spectroscopy 75Carboplatin 48Surgical Procedures, Operative 35pembrolizumab 34Radiation 34Etoposide 34Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × CUDC-907 × Clear all
NCT02909777 2026-02-11

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Dana-Farber Cancer Institute

Phase 1 Completed
26 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡